Adi Nagler, PhD
Dana-Farber Cancer Institute
Dr. Adi Nagler received her Ph.D. at the Weizmann Institute of Science in 2021, under the mentorship of Prof. Yardena Samuels. There, she spearheaded studies that identified intra-tumoral intracellular bacterial peptides eliciting an immune response by melanoma-infiltrating lymphocytes, suggesting a novel source of antigens within tumors (Kalaora & Nagler Nature 2021). As a postdoctoral fellow in Prof. Catherine Wu’s lab, she is studying the impact of the microbiome on T cell response in bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation (HCT). She is applying spatial transcriptomics methodology together with characterization of the immunopeptidome of BOS tissue specimens to define the role of bacterial presented peptides in the pathogenesis of this devastating complication of HCT. Overall, her studies aim is to explore the potential link between T cell antigen specificity to these microbial peptides and initiation and propagation of BOS.